Business · 18/11/20261 min read
New three-year real-world data on Leqembi® presented at CTAD 2026
Summary
STOCKHOLM, November 18, 2026 — BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today presented new results from the real-world Lecanemab in Early Alzheimer's Disease (LEADER) study[1]. The data showed that patients treated with Leqembi had a 76% lower rate of...